The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas

被引:0
|
作者
A Pemov
H Li
R Patidar
N F Hansen
S Sindiri
S W Hartley
J S Wei
A Elkahloun
S C Chandrasekharappa
J F Boland
S Bass
J C Mullikin
J Khan
B C Widemann
M R Wallace
D R Stewart
机构
[1] Clinical Genetics Branch,Division of Cancer Epidemiology and Genetics
[2] National Cancer Institute,Department of Molecular Genetics and Microbiology
[3] UF Genetics Institute,Division of Cancer Epidemiology and Genetics
[4] UF Health Cancer Center,Division of Cancer Epidemiology and Genetics
[5] University of Florida,undefined
[6] Genetics Branch,undefined
[7] Center for Cancer Research,undefined
[8] National Cancer Institute,undefined
[9] Cancer Genetics and Comparative Genomics Branch,undefined
[10] National Human Genome Research Institute,undefined
[11] Human Genetics Program,undefined
[12] National Cancer Institute,undefined
[13] NIH Intramural Sequencing Center,undefined
[14] National Human Genome Research Institute,undefined
[15] Cancer Genomics Research Laboratory,undefined
[16] National Cancer Institute,undefined
[17] Pediatric Oncology Branch,undefined
[18] Center for Cancer Research,undefined
[19] National Cancer Institute,undefined
来源
Oncogene | 2017年 / 36卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Neurofibromatosis type 1 (NF1) is a common tumor-predisposition disorder due to germline mutations in the tumor suppressor gene NF1. A virtually pathognomonic finding of NF1 is the plexiform neurofibroma (PN), a benign, likely congenital tumor that arises from bi-allelic inactivation of NF1. PN can undergo transformation to a malignant peripheral nerve sheath tumor, an aggressive soft-tissue sarcoma. To better understand the non-NF1 genetic contributions to PN pathogenesis, we performed whole-exome sequencing, RNASeq profiling and genome-wide copy-number determination for 23 low-passage Schwann cell cultures established from surgical PN material with matching germline DNA. All resected tumors were derived from routine debulking surgeries. None of the tumors were considered at risk for malignant transformation at the time; for example, there was no pain or rapid growth. Deep (~500X) NF1 exon sequencing was also conducted on tumor DNA. Non-NF1 somatic mutation verification was performed using the Ampliseq/IonTorrent platform. We identified 100% of the germline NF1 mutations and found somatic NF1 inactivation in 74% of the PN. One individual with three PNs had different NF1 somatic mutations in each tumor. The median number of somatic mutations per sample, including NF1, was one (range 0–8). NF1 was the only gene that was recurrently somatically inactivated in multiple tumors. Gene Set Enrichment Analysis of transcriptome-wide tumor RNA sequencing identified five significant (FDR<0.01) and seven trending (0.01⩽FDR<0.02) gene sets related to DNA replication, telomere maintenance and elongation, cell cycle progression, signal transduction and cell proliferation. We found no recurrent non-NF1 locus copy-number variation in PN. This is the first multi-sample whole-exome and whole-transcriptome sequencing study of NF1-associated PN. Taken together with concurrent copy-number data, our comprehensive genetic analysis reveals the primacy of NF1 loss as the driver of PN tumorigenesis.
引用
收藏
页码:3168 / 3177
页数:9
相关论文
共 50 条
  • [31] Neurofibromatosis type 1-associated plexiform neurofibromas of the neck: topography of lesions and surgical treatment data of 69 patients
    Reinhard E. Friedrich
    Daniel M. Löhmann
    Oral and Maxillofacial Surgery, 2024, 28 : 393 - 404
  • [32] Growth type of plexiform neurofibromas in NF1 determined on magnetic resonance images
    Friedrich, RE
    Korf, B
    Fünsterer, C
    Mautner, VF
    ANTICANCER RESEARCH, 2003, 23 (2A) : 949 - 952
  • [33] Neurofibromatosis type 1 (NF1) and Associated Tumors
    Rosenbaum, T.
    Wimmer, K.
    KLINISCHE PADIATRIE, 2014, 226 (6-7): : 309 - 315
  • [34] Neurofibromatosis 1 (NF1) deletions are restricted to S-100-positive cells in plexiform neurofibromas.
    Gutmann, D
    Roth, K
    Banerjee, R
    Perry, A
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (05): : 540 - 540
  • [35] TRAMETINIB FOR ORBITAL PLEXIFORM NEUROFIBROMAS IN YOUNG CHILDREN WITH NF1
    Toledano, Helen
    Dotan, Gad
    Friedland, Rivka
    Cohen, Rony
    Yassur, Iftach
    Toledano, Hagit
    Constantini, Shlomi
    Rootman, Mika Shapira
    NEURO-ONCOLOGY, 2020, 22 : 418 - 418
  • [36] Volumetric MRI in Neurofibromatosis Type 1 (NF1) Comes of Age to Help Determine Initiation and Monitoring of Targeted Therapies for Plexiform Neurofibromas
    Viskochil, David
    Linscott, Luke L.
    ACADEMIC RADIOLOGY, 2018, 25 (02) : 141 - 143
  • [38] Resection of Plexiform Neurofibromas in Children With Neurofibromatosis Type 1
    Canavese, Federico
    Krajbich, Joseph I.
    JOURNAL OF PEDIATRIC ORTHOPAEDICS, 2011, 31 (03) : 303 - 311
  • [39] Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1
    Ahlawat, Shivani
    Ly, K. Ina
    Fayad, Laura M.
    Fisher, Michael J.
    Lessing, Andres J.
    Berg, Dale J.
    Salamon, Johannes M.
    Mautner, Victor-Felix
    Babovic-Vuksanovic, Dusica
    Dombi, Eva
    Harris, Gordon
    Plotkin, Scott R.
    Blakeley, Jaishri
    NEUROLOGY, 2021, 97 (07) : S111 - S119
  • [40] Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas
    Tucker, T.
    Friedman, J. M.
    Friedrich, R. E.
    Wenzel, R.
    Fuensterer, C.
    Mautner, V-F
    JOURNAL OF MEDICAL GENETICS, 2009, 46 (02) : 81 - 85